Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
, Encourages Investors with Losses to Contact Firm - EconoTimes)
NEW YORK, Sept. 29, 2016 -- Scott + Scott, Attorneys at Law, LLP, a global shareholder rights litigation firm, has opened an investigation on behalf of investors in Zosano Pharma Corp (ZSAN). The investigation focuses on whether Zosano and certain of its executives and directors made false statements to investors about the Company’s osteoporosis drug program, ZP-PTH, and its collaboration agreement with Eli Lily and Company.
Investors who own Zosano stock are encouraged to contact Scott + Scott at (646)-582-0121 or email [email protected] to discuss their legal rights.
Scott + Scott, LLP is investigating potential violations of the federal securities laws in connection with the Company’s January 27, 2015 Initial Public Offering (“IPO”). In particular, the firm is investigating whether Zosano and certain of its executives and directors made false statements and omitted material information about the Company’s osteoporosis drug program, ZP-PTH, and its collaboration agreement with Eli Lily and Company.
What You Can Do
If you purchased shares of Zosano, you may have legal claims against the Company. If you wish to discuss the investigation, or have questions about your legal rights, please contact Joseph Halloran, Esq. by telephone at (646)-582-0121 or by email at [email protected].
About Scott + Scott, Attorneys at Law, LLP
Scott + Scott, Attorneys at Law, LLP has significant experience prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm has offices in New York, London, Connecticut, California and Ohio. Please visit www.scott-scott.com for more information about the firm.
Contact Scott + Scott, Attorneys at Law, LLP Joseph Halloran 646.582.0121 [email protected]
